markets

Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day

Summarized from All Financial Services & Investing

Clinical-stage biotech Windward Bio priced its IPO at $17 per share and closed its first trading day at $28.50 on Nasdaq.

Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day

Windward Bio, a Shanghai-rooted clinical-stage biotechnology company backed by Qiming Venture Partners, made its public market debut on Nasdaq on November 13, 2026, under the ticker symbol WWB, the company announced Friday.

The immunology-focused biotech priced its initial public offering at $17.00 per share, then saw strong first-day demand push its closing price to $28.50 — a gain of roughly 68 percent from the IPO price, signaling robust investor appetite for the offering.

Read more Inverse Anthropic ETFs Offer Bears Two Ways to Short ANT Stock →

Windward Bio operates as a portfolio company of Qiming Venture Partners, a prominent venture capital firm with deep roots in the Chinese technology and life sciences sectors. The listing marks a significant milestone for the company as it advances its clinical-stage immunology pipeline with access to U.S. public capital markets.

The Nasdaq listing positions Windward Bio alongside a competitive cohort of biotech companies seeking to translate early-stage immunological research into approved therapies. A first-day pop of this magnitude reflects broader market interest in innovative biotech platforms, though clinical-stage companies carry inherent pipeline risk that investors will continue to monitor as the firm progresses its programs.

Continue reading at All Financial Services & Investing.

Frequently Asked Questions

Q.What price did Windward Bio set for its IPO?

Windward Bio priced its initial public offering at $17.00 per share ahead of its Nasdaq debut on November 13, 2026.

Q.What is Windward Bio's Nasdaq ticker symbol?

Windward Bio trades on the Nasdaq exchange under the ticker symbol WWB.

Q.Who is the venture capital backer behind Windward Bio?

Windward Bio is a portfolio company of Qiming Venture Partners, which supported the clinical-stage biotech through to its public listing.

More in markets →